Last reviewed · How we verify
Placebo of NICOTINE Transdermal patch
This is a placebo control formulation containing no active nicotine, used as a comparator in clinical trials to assess the true efficacy of nicotine transdermal patches.
This is a placebo control formulation containing no active nicotine, used as a comparator in clinical trials to assess the true efficacy of nicotine transdermal patches. Used for Placebo control for nicotine replacement therapy trials in smoking cessation.
At a glance
| Generic name | Placebo of NICOTINE Transdermal patch |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert formulations designed to match the appearance and delivery method of the active drug but contain no pharmacologically active ingredient. In this case, it mimics a nicotine transdermal patch but delivers no nicotine, allowing researchers to isolate the therapeutic effect of nicotine from placebo response and natural disease progression in phase 3 trials.
Approved indications
- Placebo control for nicotine replacement therapy trials in smoking cessation
Common side effects
Key clinical trials
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- Semaglutide for Post-Smoking Cessation Weight Management (PHASE2)
- Reward Sensitivity and Pharmacotherapy for Smoking Cessation (PHASE4)
- Varenicline and Combined NRT for Smoking Cessation (PHASE4)
- Depressed Mood Improvement Through Nicotine Dosing 3 (PHASE2)
- Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Undergoing Thoracic Surgery: A Randomized Controlled Pilot Study (NA)
- Memory Improvement Through Nicotine Dosing (MIND) Study (PHASE2)
- Evaluation of the Electronic Cigarette Withdrawal Syndrome (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: